The CMS 2026 final rule, explained for ASC operators

The CY 2026 OPPS/ASC final rule is the most consequential Medicare policy change for surgery centers in years. Stripped of the rulemaking language, it does two big things: it adds 560 procedures to the ASC Covered Procedures List, and it begins phasing out the Inpatient Only (IPO) list — the catalog of roughly 1,700 procedures Medicare had previously reimbursed only in hospital inpatient settings.

For ASC operators, this isn’t an abstract regulatory update. It’s a formal invitation from the largest payer in the country to take on more surgical volume — and a test of whether your center’s operations can absorb it.

What changed

• The ASC Covered Procedures List grew by 560 procedures. Medicare’s approved ASC list has been expanding for two decades — from roughly 2,500 procedures in the mid-2000s to nearly 4,000 today — but this is one of the largest single-year additions on record.
• The Inpatient Only list is being phased out. The IPO list has been the primary regulatory barrier holding higher-acuity procedures inside hospitals. Its phase-out removes that barrier progressively, opening the path for further migration of procedures into outpatient settings over the coming years.

Why CMS is doing this

Follow the money and the clinical evidence — they point the same direction. Procedures performed in ASCs typically cost 30–50% less than the same procedures in hospital outpatient departments, and advances in minimally invasive technique, anesthesia protocols, and post-operative recovery pathways have made outpatient delivery safe for an expanding set of cases. Payers have spent a decade steering volume toward lower-cost sites of care through benefit design, narrow networks, and prior authorization. The 2026 rule aligns Medicare policy with where the clinical evidence and the economics already were.

What it means for your center

Case mix will get richer — and harder to run

The procedures migrating out of hospitals skew higher-acuity: more spine, total joint, complex GI and ENT, and select cardiovascular work. That’s higher revenue per case, and it’s also longer and more variable case durations, heavier implant logistics, more demanding anesthesia coordination, and tighter recovery workflows. The simple, predictable operating model many centers were built around doesn’t survive this shift unchanged — the centers that win the new volume will be the ones whose scheduling, staffing, and supply operations can flex with it.

Medicare coverage is the door, not the room

A procedure appearing on the ASC list means Medicare will pay for it in your setting. It doesn’t mean your commercial contracts cover it at workable rates, your state’s regulations and licensure permit it, your credentialing supports it, or your clinical team wants it. Treat the list as a menu of options to evaluate, not a mandate.

A working checklist for operators

1. Map the new list against your capabilities. Which of the 560 additions match your specialties, equipment, and clinical comfort? Shortlist the realistic candidates.
2. Model the economics per procedure. Reimbursement minus implant and supply cost, staffing intensity, and expected case duration — not just the facility fee headline.
3. Open payer conversations early. Commercial coverage and rates for newly ASC-eligible codes lag Medicare. Getting these codes into your contracts is a negotiation, and it rewards centers that arrive with data.
4. Stress-test capacity before committing. If your ORs run at 60–65% utilization, the capacity likely exists — but higher-acuity cases with variable durations punish sloppy scheduling. Know your real utilization first (our calculator is a fast start).
5. Plan anesthesia and recovery for longer cases. Higher-acuity procedures change coverage requirements and PACU time. Templates built for a cataract line won’t hold for total joints.
6. Get ahead of implant and supply logistics. New procedure lines mean new vendors, new preference cards, and new working capital tied up in inventory — decisions worth making deliberately rather than case by case.

The bigger picture

More than half of the procedures eligible for ambulatory settings are already performed outside hospitals, and the 2026 rule signals the migration has policy tailwind for years to come. The constraint on ASC growth is shifting from what you’re allowed to do to what your operation can execute well. That’s the gap Perivanta is being built to close — our reasoning is here.

This explainer is general information for operators, not billing, legal, or reimbursement advice. For rule text and payment specifics, consult the CY 2026 OPPS/ASC final rule directly at cms.gov and your billing and legal advisors.